Journal
MICROORGANISMS
Volume 10, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/microorganisms10020362
Keywords
HSV-1; herpes simplex virus; reactivation; intensive care; COVID-19; SARS-CoV-2; BALF
Categories
Ask authors/readers for more resources
Reactivation of HSV-1 is frequently detected in intubated patients with COVID-19, requiring possible antiviral treatment. However, no independent predictors of HSV-1 reactivation were identified in this study, and no association was found between HSV-1 reactivation and patient mortality.
Reactivation of herpes simplex virus type 1 (HSV-1) has been described in critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia. In the present two-center retrospective experience, we primarily aimed to assess the cumulative risk of HSV-1 reactivation detected on bronchoalveolar fluid (BALF) samples in invasively ventilated COVID-19 patients with worsening respiratory function. The secondary objectives were the identification of predictors for HSV-1 reactivation and the assessment of its possible prognostic impact. Overall, 41 patients met the study inclusion criteria, and 12/41 patients developed HSV-1 reactivation (29%). No independent predictors of HSV-1 reactivation were identified in the present study. No association was found between HSV-1 reactivation and mortality. Eleven out of 12 patients with HSV-1 reactivation received antiviral therapy with intravenous acyclovir. In conclusion, HSV-1 reactivation is frequently detected in intubated patients with COVID-19. An antiviral treatment in COVID-19 patients with HSV-1 reactivation and worsening respiratory function might be considered.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available